AstraZeneca partners with tiny Biotech

It's up BIG 👏                                                                                                                                                                                                                                                                                                                                                                                                                 August 08, 2024 | [Read Online]( *together with Brooks Enterprises Good day, 360! Here are our TOP movers today. And don’t forget to join us in [Market Masters Trading Room](. Even freeloaders are welcome… FOCUS LIST🔎 CDT - up over 100% in the pre-market after entering into exclusive license agreement with AstraZeneca for multiple assets to advance potential first-in-class treatments WENA - Up over 40% in pre after announcing that patents have been Issued in major asian markets for use of genetic therapy in the treatment of Alzheimer’s disease and ALS MVIS- Up over 10% in pre after reporting positive revenue growth *together with Brooks Enterprises Can an AI trading bot hunt for the best trades 24 hours a day?  Stephen Brooks says YES with his Trade Fusion System. Join him TONIGHT to add this weapon to your war chest! [Register here for his LIVE webinar Thursday 7pm EST]( Once you register, you’ll receive THIS 👆sneak peak! HOTLIST🔥 CDT - up over 100% in the pre-market after entering into exclusive license agreement with AstraZeneca for multiple assets to advance potential first-in-class treatments Conduit Pharmaceuticals Inc. (CDT) is a clinical-stage specialty biopharmaceutical company that develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. In the pre-market this morning, the [company announced]( that it had entered into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting autoimmune indications and myeloperoxidase inhibitor AZD5904 targeting idiopathic male infertility Assets have shown favorable preclinical and Phase I data. Conduit to initiate Phase II clinical trials. Conduit initially intends to conduct Phase II clinical trials on clinical candidates AZD1656 and AZD5658 in 2024 for applications in autoimmune disorders, a category which affect an estimated 10% of the population1. Under the terms of the License Agreement, AstraZeneca will grant Conduit an exclusive license to both AZD1656 and AZD5658 for all human indications, as well as an exclusive license to AZD5904 for use in Idiopathic Male Infertility. As part of the License Agreement, AstraZeneca will be issued shares of common stock in Conduit, and Conduit will also pay AstraZeneca a share of sublicense revenues, including upfront payments, milestones, and royalties received from future partners. AstraZeneca will share pre-clinical and clinical data on the assets and supply Conduit. Shares of CDT traded up over 100% in the pre-market in reaction to the news. The first target for bulls is the pre-market high at $0.3992. Beyond that, $0.45, $0.50, $0.60, $0.80 and $1 come into play. Below $0.3992, targets to the downside are $0.35, $0.32, $0.30, $0.27, $0.24 and then a gap fill at $0.1650. WENA - Up over 40% in pre after announcing that patents have been Issued in major asian markets for use of genetic therapy in the treatment of Alzheimer’s disease and ALS Anew Medical, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. In the pre-market this morning, the [company announced]( the grant and issuance of patent number HK1259628 protecting the development of novel genetic approaches for the treatment of neurodegenerative diseases to include Alzheimer’s disease, Parkinson’s diseases and amyotrophic lateral sclerosis (“ALS”). Patents issued in mainland China protect the Company’s novel secreted Klotho protein and Its gene delivery system Recent Patents issued in Hong Kong and Shanghai support protection to develop treatments for Alzheimer’s Disease and other neurodegenerative diseases. The stock traded up over 40% in the pre-market in reaction to the news. The $1.60 area acted as resistance in the pre-market and will be an important level to watch. Above it, the first target is the pre-market high at $1.73. Beyond that $2, $2.50, $3 and $3.50 come into play. Below $1.60, targets to the downside are $1.50, $1.40, $1.30, $1.23 and then a gap fill at $1.09. MVIS- Up over 10% in pre after reporting positive revenue growth MicroVision Inc. (MVIS) develops and sells lidar sensors and software used in automotive safety and autonomous driving applications. In the after-hours yesterday, the [company reported]( Q2 2024 earnings. Highlights include: Revenue for the second quarter of 2024 was $1.9 million, compared to $0.3 million for the second quarter of 2023, primarily driven by hardware sales to a long-standing customer in the agricultural market. Net loss for the second quarter of 2024 was $23.9 million, or $0.11 per share, which includes $3.4 million of non-cash, share-based compensation expense and $3.0 million of non-cash, asset impairment charge, compared to a net loss of $20.6 million, or $0.12 per share, which includes $3.9 million of non-cash, share-based compensation expense, for the second quarter of 2023. The Company ended the second quarter of 2024 with $56.7 million in cash and cash equivalents, including investment securities, compared to $73.8 million at December 31, 2023. The stock traded up over 10% in the pre-market in reaction to the positive revenue growth which is over 500% year over year. The first target for bulls is the pre-market high at $0.9596. Above it, targets to the upside are $1, $1.10, $1.15, $1.20, $1.30 and $1.39. Below $0.9596, targets to the downside are $0.92, $0.90, $0.88, $0.86 and then a gap fill at $0.8316. Did you know… Jeff’s LIVE trading his TOP ideas with members? Here he is stalking DASH yesterday - what a setup! [Upgrade to join the group as they stalk the next pick together!]( MARKET NEWS 📰 Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](